Release RSS (2.0) http://www.cision.com Release RSS(2.0) provided by Cision Sat, 04 Apr 2026 14:53:15 +0200 Release RSS (2.0) 120 32 http://www.cision.com http://feed.ne.cision.com/client/_images/CisionLogoSmall.gif Observe Medical ASA – Approval and publication of listing prospectus Observe Medical ASA – Approval and publication of listing prospectus]]> Fri, 01 Nov 2019 13:30:00 +0100 https://publish.ne.cision.com/v2.0/Release/GetDetailInLegacyFormat/2EDE94831B57323F https://publish.ne.cision.com/v2.0/Release/GetDetailInLegacyFormat/2EDE94831B57323F Observe Medical ASA, 1 November 2019: Reference is made to Navamedic ASA's ("NAVA") and Observe Medical ASA's ("Observe Medical") stock exchange announcements dated 30 October 2019 and 31 October 2019, regarding Oslo Børs' approval of Observe Medical's application for listing of its shares on Oslo Axess (the "Listing") and the completion of the demerger of NAVA, respectively.  The prospectus for the Listing (the "Prospectus") was approved by the Financial Supervisory Authority of Norway today, on 1 November 2019. The Prospectus has been published today and is available at www.observemedical.com. Hard copies of the Prospectus may be obtained by contacting Observe Medical. Observe Medical's shares will be listed on Oslo Axess on Monday 4 November 2019.   For further information, please contact: Ole Henrik Eriksen, interim CEO of Observe Medical Mobile: +47 400 62 000 E-mail: ole.henrik.eriksen@navamedic.com   About Observe Medical ASA: Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's headquarter is in Oslo and its operations are based out of Sweden. Observe Medical's initial product was Sippi®, the only digital urine meter with wireless data transfer to patient data management systems, which also prevents bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in the Nordics and Germany. Observe Medical ASA, 1 November 2019: Reference is made to Navamedic ASA's ("NAVA") and Observe Medical ASA's ("Observe Medical") stock exchange announcements dated 30 October 2019 and 31 October 2019, regarding Oslo Børs' approval of Observe Medical's application for listing of its shares on Oslo Axess (the "Listing") and the completion of the demerger of NAVA, respectively. 

The prospectus for the Listing (the "Prospectus") was approved by the Financial Supervisory Authority of Norway today, on 1 November 2019. The Prospectus has been published today and is available at www.observemedical.com. Hard copies of the Prospectus may be obtained by contacting Observe Medical.

Observe Medical's shares will be listed on Oslo Axess on Monday 4 November 2019.
 

For further information, please contact:

Ole Henrik Eriksen, interim CEO of Observe Medical
Mobile: +47 400 62 000
E-mail: ole.henrik.eriksen@navamedic.com
 

About Observe Medical ASA:
Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's headquarter is in Oslo and its operations are based out of Sweden. Observe Medical's initial product was Sippi®, the only digital urine meter with wireless data transfer to patient data management systems, which also prevents bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in the Nordics and Germany.

]]> PRM Pressrelease en Observe Medical ASA Observe Medical ASA, 1 November 2019: Reference is made to Navamedic ASA's ("NAVA") and Observe Medical ASA's ("Observe Medical") stock exchange announcements dated 30 October 2019 and 31 October 2019, regarding Oslo Børs' approval of Observe Medical's application for listing of its shares on Oslo Axess (the "Listing") and the completion of the demerger of NAVA, respectively. 

The prospectus for the Listing (the "Prospectus") was approved by the Financial Supervisory Authority of Norway today, on 1 November 2019. The Prospectus has been published today and is available at www.observemedical.com. Hard copies of the Prospectus may be obtained by contacting Observe Medical.

Observe Medical's shares will be listed on Oslo Axess on Monday 4 November 2019.
 

For further information, please contact:

Ole Henrik Eriksen, interim CEO of Observe Medical
Mobile: +47 400 62 000
E-mail: ole.henrik.eriksen@navamedic.com
 

About Observe Medical ASA:
Observe Medical develops and markets innovative hospital products that contribute to increased patient safety and a more efficient care system. The Company's headquarter is in Oslo and its operations are based out of Sweden. Observe Medical's initial product was Sippi®, the only digital urine meter with wireless data transfer to patient data management systems, which also prevents bacterial migration that can lead to urinary infections (Sippcoat®). Sippi® is CE marked and is currently being launched at selected hospitals in the Nordics and Germany.

]]> https://mb.cision.com/Public/19175/3047818/80969f08b5a0d82a.pdf Observe Medical ASA – Approval and publication of listing prospectus.pdf Observe Medical ASA Approval and publication of listing prospectus Press release in html format MAIN https://publish.ne.cision.com release.html text/html 4711 true